Showing 21-30 of 52 Results
Luis de Lecea
Professor of Psychiatry and Behavioral Sciences (Major Laboratories and Clinical and Translational Neurosciences Incubator)
Current Research and Scholarly InterestsMy lab uses molecular, optogenetic, anatomical and behavioral methods to identify and manipulate the neuronal circuits underlying brain arousal, with particular attention to sleep and wakefulness transitions. We are also interested in the changes that occur in neuronal circuits in conditions of hyperarousal such as stress and drug addiction.
Giulio De Leo
Professor of Oceans, of Earth System Science, Senior Fellow at the Woods Institute for the Environment and Professor, by courtesy of Biology
Current Research and Scholarly InterestsI am a theoretical ecologist mostly interested in investigating factors and processes driving the dynamics of natural and harvested populations and on how to use this knowledge to inform practical management. I have worked broadly on life histories analysis, fishery management, dynamics and control of infectious diseases and environmental impact assessment.
D. H. Chen Professor, Professor of Bioengineering and of Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsKarl Deisseroth's laboratory created and developed optogenetics, hydrogel-tissue chemistry (beginning with CLARITY), and a broad range of enabling methods. He also has employed his technologies to discover the neural cell types and connections that cause adaptive and maladaptive behaviors.
Daniel James Delitto, MD, PhD, FACS
Assistant Professor of Surgery (General Surgery)
BioDr. Delitto is a board certified complex general surgical oncologist with a focus on conditions of the liver, pancreas, and stomach. He is an assistant professor in Stanford Medicine’s Department of Surgery.
His education includes a decade of postgraduate training in complex general surgical oncology, as well as a PhD in immunology with an emphasis on cancer biology. He completed a clinical fellowship at Johns Hopkins University and continued his research at the postdoctoral level in the laboratory of Dr. Elizabeth Jaffee. His research focus is on advancing the field of cancer immunology and harnessing his findings to improve immunotherapies.
He was the principal investigator of two studies examining the immune response to pancreatic cancer, including one funded by the National Cancer Institute.
Dr. Delitto has presented the findings of his research at conferences such as the American Association for Cancer Research, Society for the Immunotherapy of Cancer, American Association of Immunologists, American College of Surgeons, Academic Surgical Congress and Pancreas Club. In addition to cancer immunology, he has also presented work focused on cancer cachexia, surgical outcomes, translational experimental models and a variety of other oncologic topics.
He has published original work in Nature Communications, the Journal of the National Cancer Institute, Cancer Research, Clinical Cancer Research, and other high impact journals. He is also a reviewer for Annals of Surgery, Scientific Reports, Surgery, Tumor Biology, Journal of Surgical Research, PLOS ONE, and the Journal of Translational Medicine.
Dr. Delitto has earned numerous honors related to clinical excellence, teaching and research. He is board certified by the American Board of Surgery and a member of the Society of Surgical Oncology, American Association for Cancer Research and American Association of Immunologists.
Scott L. Delp, Ph.D.
Director, Wu Tsai Human Performance Alliance at Stanford, James H. Clark Professor in the School of Engineering, Professor of Bioengineering, of Mechanical Engineering and, by courtesy, of Orthopaedic Surgery
Current Research and Scholarly InterestsExperimental and computational approaches to study human movement. Development of biomechanical models to analyze muscle function, study movement abnormalities, design medical products, and guide surgery. Imaging and health technology development. Discovering the principles of peak performance to advance human health. Human performance research. Wearable technologies, video motion capture, and machine learning to enable large-scale analysis.
Professor of Radiology (Canary Cancer Center) and, by courtesy, of Electrical EngineeringOn Partial Leave from 02/26/2024 To 02/25/2025
BioUtkan Demirci is a tenured professor in the School of Medicine at Stanford University and serves as the Interim Division Chief and Director of the Canary Center at Stanford for Cancer Early Detection in the Department of Radiology. Prior to Stanford, he was an Associate Professor of Medicine at the Brigham and Women’s Hospital, Harvard Medical School, and a faculty member of the Harvard-MIT Health Sciences and Technology division.
Professor Demirci received his PhD from Stanford University in Electrical Engineering in 2005 and holds M.S. degrees in Electrical Engineering, and in Management Science and Engineering. He has published over 200 peer-reviewed journal articles, 24 book chapters, 7 edited books, and several hundred abstracts and proceedings, as well as having over 25 patents and disclosures pending or granted. He has mentored and trained hundreds of successful scientists, entrepreneurs and academicians and fostered research and industry collaborations around the world. Dr. Demirci was awarded the NSF CAREER Award, and IEEE EMBS Early Career Award. He is currently a fellow of the the American Institute for Medical and Biological Engineering (AIMBE, 2017), and Distinguished Investigator of the Academy for Radiology and Biomedical Imaging Research and serves as an editorial board member for a number of peer-reviewed journals.
The BAMM Lab group focuses on developing innovative extracellular vesicle isolation tools, point-of-care technologies and creating microfluidic platforms for early cancer detection with broad applications to multiple diseases including infertility and HIV. Dr. Demirci’s lab has collaborated with over 50 research groups and industry partners around the world. His seminal work in microfluidics has led to the development of innovative FDA-approved platform technologies in medicine and many of his inventions have been industry licensed. He holds several FDA-approved and CE-marked technologies that have been widely used by fertility clinics with assisted reproductive technologies leading to over thousands of live births globally and in the US.
Dr. Demirci is a serial academic entrepreneur and co-founder of DxNow, Zymot, Levitas Bio, Mercury Biosciences and Koek Biotech and serves as an advisor, consultant and/or board member to some early stage companies and investment groups.
Professor of Medicine (Pulmonary, Allergy and Critical Care Medicine)
Current Research and Scholarly InterestsBasic and translational research in lung stem cell biology, cancer, pulmonary fibrosis, COPD, and acute lung injury/ARDS. Upper airway stem cell CRISPR gene correction followed by autologous stem cell transplantation to treat Cystic fibrosis. Using lung organoids and precision cut lung slice cultures of mouse and human lungs to study molecular regulation of lung stem cells. Using transgenic mice to visualize Wnt protein transmission from niche cell to stem cell in vivo.
Joseph M. DeSimone
Sanjiv Sam Gambhir Professor of Translational Medicine, Professor of Chemical Engineering and, by courtesy, of Chemistry, of Materials Science and Engineering, and of Operations, Information and Technology at the Graduate School of Business
BioJoseph M. DeSimone is the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. He holds appointments in the Departments of Radiology and Chemical Engineering with courtesy appointments in the Department of Chemistry and in Stanford’s Graduate School of Business.
The DeSimone laboratory's research efforts are focused on developing innovative, interdisciplinary solutions to complex problems centered around advanced polymer 3D fabrication methods. In Chemical Engineering and Materials Science, the lab is pursuing new capabilities in digital 3D printing, as well as the synthesis of new polymers for use in advanced additive technologies. In Translational Medicine, research is focused on exploiting 3D digital fabrication tools to engineer new vaccine platforms, enhanced drug delivery approaches, and improved medical devices for numerous conditions, with a current major focus in pediatrics. Complementing these research areas, the DeSimone group has a third focus in Entrepreneurship, Digital Transformation, and Manufacturing.
Before joining Stanford in 2020, DeSimone was a professor of chemistry at the University of North Carolina at Chapel Hill and of chemical engineering at North Carolina State University. He is also Co-founder, Board Chair, and former CEO (2014 - 2019) of the additive manufacturing company, Carbon. DeSimone is responsible for numerous breakthroughs in his career in areas including green chemistry, medical devices, nanomedicine, and 3D printing. He has published over 350 scientific articles and is a named inventor on over 200 issued patents. Additionally, he has mentored 80 students through Ph.D. completion in his career, half of whom are women and members of underrepresented groups in STEM.
In 2016 DeSimone was recognized by President Barack Obama with the National Medal of Technology and Innovation, the highest U.S. honor for achievement and leadership in advancing technological progress. He has received numerous other major awards in his career, including the U.S. Presidential Green Chemistry Challenge Award (1997); the American Chemical Society Award for Creative Invention (2005); the Lemelson-MIT Prize (2008); the NIH Director’s Pioneer Award (2009); the AAAS Mentor Award (2010); the Heinz Award for Technology, the Economy and Employment (2017); the Wilhelm Exner Medal (2019); the EY Entrepreneur of the Year Award (2019 U.S. Overall National Winner); and the Harvey Prize in Science and Technology (2020). He is one of only 25 individuals elected to all three branches of the U.S. National Academies (Sciences, Medicine, Engineering). DeSimone received his B.S. in Chemistry in 1986 from Ursinus College and his Ph.D. in Chemistry in 1990 from Virginia Tech.
Maximilian Diehn, MD, PhD
Jack, Lulu, and Sam Willson Professor and Professor of Radiation Oncology (Radiation Therapy)On Leave from 11/27/2023 To 08/30/2024
Current Research and Scholarly InterestsMy laboratory focuses on two main areas: 1) cancer stem cell biology and 2) novel biomarkers for identifying the presence of malignant cells (diagnostic), predicting outcome (prognostic), and predicting response to therapy (predictive). Areas of study include cancers of the lung, breast, and gastrointestinal system. Clinically I specialize in the treatment of lung cancer and applications of stereotactic ablative radiotherapy and perform both prospective and retrospective clinical studies.